Diabetic murine models for Acinetobacter baumannii infection

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1439-1445

  Luo, Guanpingsheng ^a   Spellberg, Brad ^a,b   Gebremariam, Teclegiorgis ^a   Bolaris, Michael ^a   Lee, Hongkyu ^a   Fu, Yue ^a,b   French, Samuel W ^a,b   Ibrahim, Ashraf S ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacteraemia; Colistin; Mice; Pneumonia

Indexed keywords

COLISTIN; PLACEBO;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DRUG EFFICACY; HISTOPATHOLOGY; INFECTION SENSITIVITY; INFLAMMATORY INFILTRATE; LUNG ALVEOLUS CELL; MORTALITY; MOUSE; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; SURVIVAL; SURVIVAL TIME; TREATMENT DURATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL LOAD; COLISTIN; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HISTOCYTOCHEMISTRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; PNEUMONIA, BACTERIAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861173590     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks050     Document Type: Article

References (39)

1. Doi Y, Husain S, Potoski BA et al. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15: 980-2.
2. Higgins PG, Dammhayn C, Hackel M et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8.
3. Choi JY, Park YS, Kim CO et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35: 599-603.
4. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51.
5. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775-80.
6. Munoz-Price LS, Zembower T, Penugonda S et al. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010; 31: 1057-62.
7. OXA-51-like genes in patients with diabetes mellitus. J Chemother 2009; 21: 290-5.
8. Furniss D, Gore S, Azadian B et al. Acinetobacter infection is associated with acquired glucose intolerance in burn patients. J Burn Care Rehabil 2005; 26: 405-8.
9. Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20: 540-4.
10. Chiang SR, Chuang YC, Tang HJ et al. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med 2009; 37: 2590-5.
11. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011; 203: 545-8.
12. Montero A, Ariza J, Corbella X et al. Efficacy of colistin versus b-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-52.
13. Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-91.
14. Pichardo C, Pachon-Ibanez ME, Docobo-Perez F et al. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 2010; 29: 527-31.
15. Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 1165-72.
16. Ibrahim AS, Avanessian V, Spellberg B et al. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47: 3343-4.
17. Ibrahim AS, Gebermariam T, Fu Y et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-57.
18. Ibrahim AS, Gebremariam T, Lin L et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010; 77: 587-604.
19. Liu M, Spellberg B, Phan QT et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120: 1914-24.
20. Ibrahim AS, Edwards JE Jr, Fu Y et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006; 58: 1070-3.
21. Luo G, Lin L, Ibrahim AS et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One 2012; 7: e29446.
22. Piechaud M, Second L. [Studies of 26 strains of Moraxella iwoffi]. Ann Inst Pasteur (Paris) 1951; 80: 97-9.
23. Gouby A, Carles-Nurit MJ, Bouziges N et al. Use of pulsed-field gel electrophoresis for investigation of hospital outbreaks of Acinetobacter baumannii. J Clin Microbiol 1992; 30: 1588-91.
24. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74: 150-60.
25. Alba-Loureiro TC, Hirabara SM, Mendonca JR et al. Diabetes causes marked changes in function and metabolism of rat neutrophils. J Endocrinol 2006; 188: 295-303.
26. Valencia R, Arroyo LA, Conde M et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009; 30: 257-63.
27. Kim YA, Choi JY, Kim CK et al. Risk factors and outcomes of bloodstream infections with metallo-b-lactamase-producing Acinetobacter. Scand J Infect Dis 2008; 40: 234-40.
28. Sheppard DC, Rieg G, Chiang LY et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004; 48: 1908-11.
29. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11: 868-73.
30. Joly-Guillou ML, Wolff M, Pocidalo JJ et al. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997; 41: 345-51.
31. Rodriguez-Hernandez MJ, Pachon J, Pichardo C et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000; 45: 493-501.
32. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
33. Song JY, Cheong HJ, Lee J et al. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009; 33: 33-9.
34. Dudhani RV, Turnidge JD, Nation RL et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65: 1984-90.
35. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150: 752-60.
36. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38: 1123-9.
37. Actis LA. Insight into innovative approaches to battle Acinetobacter baumannii infection therapy struggles. Virulence 2010; 1: 6-7.
38. Spellberg B, Fu Y, Edwards JE Jr et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830-2.
39. Jones A, Elphick H, Pettitt E et al. Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase. Eur Respir J 2002; 19: 1136-41.